🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Leading the way in leaflet modification, the #ShortCut Pivotal Study has made significant strides in the field. Recently published in the #EuropeanHeartJournal, the study highlights the innovative approach and promising results achieved with ShortCut. ✨ Key findings from the

Congratulations to Dr. Raj Makkar and the hashtag #HeartTeam at Cedars-Sinai for performing their first ShortCut case in the Continued Access Study! 👏 The patient had a failed Magna Ease valve and was at high risk of coronary obstruction. It was a smooth procedure with a dual

🚨 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦 🚨 We are thrilled to announce that 𝗣𝗶-𝗖𝗮𝗿𝗱𝗶𝗮 𝗵𝗮𝘀 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝗱 𝗙𝗗𝗔 𝗺𝗮𝗿𝗸𝗲𝘁 𝗰𝗹𝗲𝗮𝗿𝗮𝗻𝗰𝗲 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗦𝗵𝗼𝗿𝘁𝗖𝘂𝘁 device! 🎉 This is a huge milestone, as we believe ShortCut will be a game-changing leaflet

Pi-Cardia Shortcut FDA approved! What a great news! Best dedicated device to make the procedure simpler and more accessible! Congratulations investigators!

Lifetime management of aortic stenosis calls for leaflet modification solutions like ShortCut™ to ensure that we are carefully addressing the risk of coronary obstruction before implanting a valve businesswire.com/news/home/2024…

Pi-Cardia’s ShortCut Leaflet Modification Device for TAVR Cleared by FDA citoday.com/news/pi-cardia…

📣 𝗦𝗵𝗼𝗿𝘁𝗖𝘂𝘁 – 𝗧𝗵𝗲 𝗙𝗶𝗿𝘀𝘁 𝗗𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗟𝗲𝗮𝗳𝗹𝗲𝘁 𝗠𝗼𝗱𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗶𝘀 𝗡𝗼𝘄 𝗙𝗗𝗔 𝗖𝗹𝗲𝗮𝗿𝗲𝗱! Addressing lifetime management of aortic stenosis with a safe, simple and effective solution 🫀 . . . . #PiCardia #ShortCut

Want to learn more about leaflet modification? Make sure to mark your calendars with the Pi-Cardia presentations at hashtag#TCT2024 💡 Looking forward to seeing everyone in Washington DC! 🏛️ Danny Dvir Pradeep Yadav Philippe Genereux #PiCardia #ShortCut #TAVI #TAVR

Congratulations to the Heart Team at the University of Michigan for including their first patient in the #ShortCut Continued Access Study! 👏 The patient had a failed Trifecta valve and was at high risk for obstruction of both the RCC and LCC leaflets. The ShortCut procedure went smoothly with

📣 𝗛𝗲𝗮𝗿 𝗗𝗿. 𝗠𝗮𝗿𝘁𝗶𝗻 𝗕. 𝗟𝗲𝗼𝗻 𝗱𝗶𝘀𝗰𝘂𝘀𝘀 𝘁𝗵𝗲 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝗰𝗲 𝗼𝗳 𝗦𝗵𝗼𝗿𝘁𝗖𝘂𝘁™, 𝗮 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗱𝗲𝘃𝗶𝗰𝗲 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗳𝗼𝗿 𝗹𝗲𝗮𝗳𝗹𝗲𝘁 𝘀𝗽𝗹𝗶𝘁𝘁𝗶𝗻𝗴, 𝗮𝗻𝗱 𝗶𝘁𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝘁𝗵𝗲

What a fantastic week at #TCT2024! 🎉 It was a great opportunity to connect with friends and colleagues, and the excitement surrounding ShortCut and its recent FDA clearance was truly inspiring 🌟 A sincere thank you to our key experts for their outstanding presentations on

Heading to PCR London Valves! 🇬🇧 Excited to join this global cardiology community and see the latest advancements in leaflet modification 💡 . . . PCRonline 🫀 #PCRLV2024 #PCRLondonValves #PiCardia #ShortCut #TAVI #TAVR #AorticValve #AorticStenosis #ValveinValve #VIV #Innovation

✨ What an incredible PCR London Valves! ✨ Three days filled with meaningful innovation and education with the latest advancements in the field. We are thrilled to be part of a community pushing boundaries and improving patient outcomes. A huge thank you to our key experts for

ShortCut Continued Access Study Completes Enrollment! 🎉 An outstanding ShortCut case was performed by Dr. Saibal Kar, Dr. Greg Fontana, and the #HeartTeam at Los Robles Regional Medical Center. The team successfully split both the LCC and RCC leaflets in just 20 minutes, enabling a safe TAVR with

🚨 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦 🚨 𝗦𝗵𝗼𝗿𝘁𝗖𝘂𝘁 𝗶𝘀 𝗼𝗳𝗳 𝘁𝗼 𝗮𝗻 𝗶𝗻𝗰𝗿𝗲𝗱𝗶𝗯𝗹𝗲 𝘀𝘁𝗮𝗿𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗨𝗦! 🚀 The first week of commercialization demonstrated strong demand, with leading structural heart centers successfully treating patients with #ShortCut,

Pi-Cardia’s ShortCut Leaflet Modification Device for TAVR Used in First Commercial Procedures | Pi-Cardia citoday.com/news/pi-cardia…

ShortCut™ is transforming complex TAVR procedures with its innovative approach to leaflet modification. ✨ Esteemed cardiologists 👨‍⚕️ Dr. Hemal Gada, Dr. Philippe Généreux, and Dr. Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI share their expert insights on this advancement.